DK2939026T3 - IMAGE ANALYSIS FOR BREAST CANCER PROGRESS - Google Patents
IMAGE ANALYSIS FOR BREAST CANCER PROGRESS Download PDFInfo
- Publication number
- DK2939026T3 DK2939026T3 DK13815724.3T DK13815724T DK2939026T3 DK 2939026 T3 DK2939026 T3 DK 2939026T3 DK 13815724 T DK13815724 T DK 13815724T DK 2939026 T3 DK2939026 T3 DK 2939026T3
- Authority
- DK
- Denmark
- Prior art keywords
- score
- heterogeneity
- her2
- breast cancer
- view
- Prior art date
Links
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 144
- 206010006187 Breast cancer Diseases 0.000 title claims description 143
- 238000010191 image analysis Methods 0.000 title description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 155
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 153
- 102000015694 estrogen receptors Human genes 0.000 claims description 147
- 108010038795 estrogen receptors Proteins 0.000 claims description 147
- 238000000034 method Methods 0.000 claims description 124
- 102000003998 progesterone receptors Human genes 0.000 claims description 111
- 108090000468 progesterone receptors Proteins 0.000 claims description 111
- 238000004393 prognosis Methods 0.000 claims description 99
- 239000000090 biomarker Substances 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 230000014509 gene expression Effects 0.000 claims description 57
- 238000005259 measurement Methods 0.000 claims description 29
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 6
- 210000001165 lymph node Anatomy 0.000 claims description 5
- 230000002055 immunohistochemical effect Effects 0.000 claims 7
- 230000001186 cumulative effect Effects 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 230000001955 cumulated effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 94
- 238000003364 immunohistochemistry Methods 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 85
- 210000001519 tissue Anatomy 0.000 description 81
- 210000004940 nucleus Anatomy 0.000 description 67
- 238000010186 staining Methods 0.000 description 48
- 206010028980 Neoplasm Diseases 0.000 description 38
- 238000005516 engineering process Methods 0.000 description 32
- 210000000481 breast Anatomy 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 21
- 238000012545 processing Methods 0.000 description 20
- 238000010586 diagram Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 238000003860 storage Methods 0.000 description 17
- -1 docetaxel) Chemical compound 0.000 description 16
- 238000004364 calculation method Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004891 communication Methods 0.000 description 13
- 239000012528 membrane Substances 0.000 description 12
- 238000010606 normalization Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000000834 fixative Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000011218 segmentation Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 239000000107 tumor biomarker Substances 0.000 description 3
- 101100509468 Arabidopsis thaliana JASON gene Proteins 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 239000011547 Bouin solution Substances 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000000265 Lobular Carcinoma Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000003714 breast lobular carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004883 computer application Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
- 101000738977 Homo sapiens Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108020000002 NR3 subfamily Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 201000011063 cribriform carcinoma Diseases 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091008584 nuclear progesterone receptors Proteins 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000013390 scatchard method Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747148P | 2012-12-28 | 2012-12-28 | |
| PCT/EP2013/077295 WO2014102130A1 (en) | 2012-12-28 | 2013-12-19 | Image analysis for breast cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2939026T3 true DK2939026T3 (en) | 2017-09-11 |
Family
ID=49917058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13815724.3T DK2939026T3 (en) | 2012-12-28 | 2013-12-19 | IMAGE ANALYSIS FOR BREAST CANCER PROGRESS |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11211167B2 (enExample) |
| EP (1) | EP2939026B1 (enExample) |
| JP (1) | JP6405319B2 (enExample) |
| AU (1) | AU2013369439B2 (enExample) |
| CA (1) | CA2890964C (enExample) |
| DK (1) | DK2939026T3 (enExample) |
| ES (1) | ES2639559T3 (enExample) |
| WO (1) | WO2014102130A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220187301A1 (en) * | 2018-09-14 | 2022-06-16 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105008919B (zh) * | 2013-03-06 | 2018-11-13 | 生物研究技术公司 | 分子成像和相关方法 |
| EP3155592B1 (en) * | 2014-06-10 | 2019-09-11 | Leland Stanford Junior University | Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides |
| EP3227833B1 (en) * | 2014-12-03 | 2024-12-25 | Ventana Medical Systems, Inc. | Systems and methods for early-stage cancer prognosis |
| US9953133B2 (en) | 2015-06-03 | 2018-04-24 | General Electric Company | Biological data annotation and visualization |
| US10672505B2 (en) | 2015-06-03 | 2020-06-02 | General Electric Company | Biological data annotation and visualization |
| US9613254B1 (en) | 2015-09-30 | 2017-04-04 | General Electric Company | Quantitative in situ characterization of heterogeneity in biological samples |
| US20170234874A1 (en) * | 2015-10-07 | 2017-08-17 | Clearbridge Biophotonics Pte Ltd. | Integrated visual morphology and cell protein expression using resonance-light scattering |
| WO2018118786A1 (en) * | 2016-12-19 | 2018-06-28 | Ventana Medical Systems, Inc. | Methods and systems for quantitative immunohistochemistry |
| JP7278224B2 (ja) * | 2017-06-02 | 2023-05-19 | コーニンクレッカ フィリップス エヌ ヴェ | 医用画像の病変の定量化される態様 |
| CN107271671A (zh) * | 2017-06-05 | 2017-10-20 | 龚畅 | 一种预测er（+）乳腺癌新辅助化疗效果的试剂盒和系统 |
| US10586376B2 (en) * | 2017-06-13 | 2020-03-10 | Optrascan, Inc. | Automated method of predicting efficacy of immunotherapy approaches |
| RU2664671C1 (ru) * | 2017-07-28 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ прогноза рака молочной железы |
| CN111448584B (zh) * | 2017-12-05 | 2023-09-26 | 文塔纳医疗系统公司 | 计算肿瘤空间和标记间异质性的方法 |
| JP7197584B2 (ja) * | 2017-12-06 | 2022-12-27 | ベンタナ メディカル システムズ， インコーポレイテッド | デジタル病理学分析結果の格納および読み出し方法 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| EP3721373B1 (en) | 2017-12-07 | 2025-03-05 | Ventana Medical Systems, Inc. | Deep-learning systems and methods for joint cell and region classification in biological images |
| EP3729369A2 (en) | 2017-12-24 | 2020-10-28 | Ventana Medical Systems, Inc. | Computational pathology approach for retrospective analysis of tissue-based companion diagnostic driven clinical trial studies |
| US11621058B2 (en) | 2018-02-08 | 2023-04-04 | Ohio State Innovation Foundation | Synthetic IHC-stained digital sides generated using artificial neural networks |
| WO2019197509A1 (en) | 2018-04-13 | 2019-10-17 | Ventana Medical Systems, Inc. | Systems for cell shape estimation |
| US12020493B2 (en) | 2018-07-27 | 2024-06-25 | Ventana Medical Systems, Inc. | Systems for automated in situ hybridization analysis |
| WO2020046773A1 (en) | 2018-08-31 | 2020-03-05 | Ventana Medical Systems, Inc. | Contextually adaptive digital pathology interface |
| JP7228031B2 (ja) | 2018-10-15 | 2023-02-22 | ベンタナ メディカル システムズ， インコーポレイテッド | 細胞の分類のためのシステムおよび方法 |
| CN113226157B (zh) * | 2018-12-19 | 2025-03-18 | 匹兹堡大学高等教育联邦体系 | 用于原位或体外多参数细胞和亚细胞成像数据的计算系统病理学空间分析平台 |
| JP7227389B2 (ja) | 2019-02-13 | 2023-02-21 | ベンタナ メディカル システムズ， インコーポレイテッド | マルチチャネル画像における自己蛍光の寄与を算出するシステムおよび方法 |
| JP7593112B2 (ja) * | 2019-02-15 | 2024-12-03 | コニカミノルタ株式会社 | 情報提供方法、情報提供装置及びプログラム |
| US11726757B2 (en) * | 2019-08-14 | 2023-08-15 | Nvidia Corporation | Processor for performing dynamic programming according to an instruction, and a method for configuring a processor for dynamic programming via an instruction |
| EP4022286A1 (en) | 2019-08-28 | 2022-07-06 | Ventana Medical Systems, Inc. | Label-free assessment of biomarker expression with vibrational spectroscopy |
| KR20220064379A (ko) | 2019-09-09 | 2022-05-18 | 페이지.에이아이, 인크. | 바이오마커들을 추론하기 위해 슬라이드의 이미지들을 처리하기 위한 시스템들 및 방법들 |
| CN110853022B (zh) * | 2019-11-14 | 2020-11-06 | 腾讯科技（深圳）有限公司 | 病理切片图像的处理方法、装置、系统及存储介质 |
| WO2021146705A1 (en) | 2020-01-19 | 2021-07-22 | Ventana Medical Systems, Inc. | Non-tumor segmentation to support tumor detection and analysis |
| CN115088022A (zh) | 2020-02-11 | 2022-09-20 | 文塔纳医疗系统公司 | 用于训练机器学习算法和维护患者隐私的联邦学习系统 |
| US20210287801A1 (en) * | 2020-03-11 | 2021-09-16 | Biosyntagma, Inc. | Method for predicting disease state, therapeutic response, and outcomes by spatial biomarkers |
| CN115552534A (zh) * | 2020-03-18 | 2022-12-30 | 赛诺菲 | 用于预测表达水平的系统和方法 |
| CN115997241A (zh) * | 2020-08-13 | 2023-04-21 | 佩治人工智能公司 | 处理电子图像进行连续生物标志物预测的系统和方法 |
| DE102020211271A1 (de) * | 2020-09-08 | 2022-03-10 | Siemens Healthcare Gmbh | Erzeugung eines Biomarkers quantifizierend eine räumliche Homogenität einer medizinischen Parameterkarte |
| EP4217393A1 (en) * | 2020-09-22 | 2023-08-02 | Ventana Medical Systems, Inc. | Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin |
| CN112801939B (zh) * | 2020-12-31 | 2022-07-22 | 杭州迪英加科技有限公司 | 一种用于提高病理图像ki67指标准确性的方法 |
| US20240295561A1 (en) * | 2021-06-17 | 2024-09-05 | Konica Minolta, Inc. | Quantification method and labeling method |
| CN113970638B (zh) * | 2021-10-24 | 2023-02-03 | 清华大学 | 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用 |
| CN119654686A (zh) * | 2022-08-08 | 2025-03-18 | 文塔纳医疗系统公司 | 用于对数字化病理学载玻片的定量的系统和方法 |
| WO2024178422A1 (en) * | 2023-02-24 | 2024-08-29 | Ohio State Innovation Foundation | Novel image-based metrics of her2 heterogeneity |
| WO2024259271A2 (en) * | 2023-06-15 | 2024-12-19 | New York University | Systems, methods and computer-accessible medium for determining and/or analysing cancer outcome(s) and/or treatment responses |
| WO2025014787A1 (en) * | 2023-07-07 | 2025-01-16 | Ventana Medical Systems, Inc. | Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells |
| WO2025106811A1 (en) * | 2023-11-15 | 2025-05-22 | 4D Path Inc. | Systems and methods for image-based disease characterization |
| KR20250156974A (ko) | 2024-04-26 | 2025-11-04 | 사회복지법인 삼성생명공익재단 | 딥러닝 모델을 이용한 종양 미세환경 예측 방법 및 분석장치 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444487A (en) | 1979-07-02 | 1984-04-24 | Xerox Corporation | Multiple-flash fuser |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| EP0256654B1 (en) | 1986-07-07 | 1996-09-18 | Centocor, Inc. | Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
| GB0229734D0 (en) | 2002-12-23 | 2003-01-29 | Qinetiq Ltd | Grading oestrogen and progesterone receptors expression |
| US20050136549A1 (en) * | 2003-10-30 | 2005-06-23 | Bioimagene, Inc. | Method and system for automatically determining diagnostic saliency of digital images |
| US8787651B2 (en) * | 2010-09-28 | 2014-07-22 | Flagship Biosciences, LLC | Methods for feature analysis on consecutive tissue sections |
| US9286672B2 (en) * | 2012-01-10 | 2016-03-15 | Rutgers, The State University Of New Jersey | Integrated multivariate image-based method for disease outcome predicition |
| JP2013200287A (ja) | 2012-03-26 | 2013-10-03 | Kawasaki Gakuen | Ｋｉ−６７インデックス算定二重染色法を用いた陽性率測定方法 |
-
2013
- 2013-12-19 CA CA2890964A patent/CA2890964C/en active Active
- 2013-12-19 EP EP13815724.3A patent/EP2939026B1/en active Active
- 2013-12-19 JP JP2015550033A patent/JP6405319B2/ja active Active
- 2013-12-19 DK DK13815724.3T patent/DK2939026T3/en active
- 2013-12-19 WO PCT/EP2013/077295 patent/WO2014102130A1/en not_active Ceased
- 2013-12-19 US US14/653,831 patent/US11211167B2/en active Active
- 2013-12-19 AU AU2013369439A patent/AU2013369439B2/en active Active
- 2013-12-19 ES ES13815724.3T patent/ES2639559T3/es active Active
-
2021
- 2021-10-28 US US17/512,812 patent/US20220051804A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220187301A1 (en) * | 2018-09-14 | 2022-06-16 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2939026A1 (en) | 2015-11-04 |
| JP2016503167A (ja) | 2016-02-01 |
| JP6405319B2 (ja) | 2018-10-17 |
| CA2890964A1 (en) | 2014-07-03 |
| WO2014102130A1 (en) | 2014-07-03 |
| CA2890964C (en) | 2023-07-25 |
| AU2013369439A1 (en) | 2015-05-28 |
| ES2639559T3 (es) | 2017-10-27 |
| US20150347702A1 (en) | 2015-12-03 |
| US20220051804A1 (en) | 2022-02-17 |
| US11211167B2 (en) | 2021-12-28 |
| EP2939026B1 (en) | 2017-07-05 |
| AU2013369439B2 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220051804A1 (en) | Image Analysis for Breast Cancer Prognosis | |
| KR102179848B1 (ko) | 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용 | |
| Lloyd et al. | Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? | |
| Cuzick et al. | Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer | |
| Zhong et al. | A comparison of visual assessment and automated digital image analysis of Ki67 labeling index in breast cancer | |
| Brügmann et al. | Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains | |
| Niikura et al. | Prognostic significance of the Ki67 scoring categories in breast cancer subgroups | |
| Holten-Rossing et al. | Optimizing HER2 assessment in breast cancer: application of automated image analysis | |
| CN112789684B (zh) | 用于预测对pd-1轴导向疗法的应答的方法和系统 | |
| Varga et al. | Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study | |
| JP2018504674A (ja) | 早期癌予知のための計算病理学システム及び方法 | |
| Balkenhol et al. | Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics | |
| JP5866362B2 (ja) | 画像解析による固形腫瘍進行の予後検査 | |
| Zbytek et al. | Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score | |
| Ahn et al. | Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens. | |
| CN110168561B (zh) | 用于确定一个或多个组织样本中的细胞组成信息的装置 | |
| Qi et al. | Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients | |
| Kim et al. | Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers | |
| JP2015525358A (ja) | 組織切片中の単一細胞におけるマーカー定量 | |
| Cho et al. | The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value | |
| Roberts et al. | Reliability of a computational platform as a surrogate for manually interpreted immunohistochemical markers in breast tumor tissue microarrays | |
| Nassar et al. | Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens | |
| Miller et al. | Objective analysis of cancer stem cell marker expression using immunohistochemistry | |
| Jing et al. | Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer | |
| CN115552248A (zh) | 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法 |